- Home
- AMIX vs BCLI Comparison
AMIX vs BCLI Comparison
Compare AMIX & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- BCLI
- Stock Information
- Founded
- AMIX 2014
- BCLI 2000
- Country
- AMIX United States
- BCLI United States
- Employees
- AMIX N/A
- BCLI N/A
- Industry
- AMIX
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMIX
- BCLI Health Care
- Exchange
- AMIX NYSE
- BCLI Nasdaq
- Market Cap
- AMIX 5.5M
- BCLI 6.4M
- IPO Year
- AMIX N/A
- BCLI N/A
- Fundamental
- Price
- AMIX $1.97
- BCLI $0.92
- Analyst Decision
- AMIX
- BCLI Strong Buy
- Analyst Count
- AMIX 0
- BCLI 1
- Target Price
- AMIX N/A
- BCLI $30.00
- AVG Volume (30 Days)
- AMIX 13.5K
- BCLI 366.6K
- Earning Date
- AMIX 05-30-2025
- BCLI 05-13-2025
- Dividend Yield
- AMIX N/A
- BCLI N/A
- EPS Growth
- AMIX N/A
- BCLI N/A
- EPS
- AMIX N/A
- BCLI N/A
- Revenue
- AMIX N/A
- BCLI N/A
- Revenue This Year
- AMIX N/A
- BCLI N/A
- Revenue Next Year
- AMIX N/A
- BCLI N/A
- P/E Ratio
- AMIX N/A
- BCLI N/A
- Revenue Growth
- AMIX N/A
- BCLI N/A
- 52 Week Low
- AMIX $1.52
- BCLI $0.72
- 52 Week High
- AMIX $75.80
- BCLI $10.05
- Technical
- Relative Strength Index (RSI)
- AMIX 53.21
- BCLI 35.85
- Support Level
- AMIX $1.61
- BCLI $1.12
- Resistance Level
- AMIX $2.06
- BCLI $0.82
- Average True Range (ATR)
- AMIX 0.11
- BCLI 0.12
- MACD
- AMIX 0.07
- BCLI 0.01
- Stochastic Oscillator
- AMIX 82.59
- BCLI 36.36
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.